Cardiometabolic Disorders News

Endocrinology providers and researchers will gather in Boston beginning Saturday as the Endocrine Society holds its 2024 annual meeting.

A selective cortisol modulator was linked to lower odds for loss of blood pressure control among adults with Cushing’s syndrome compared with placebo, according to topline results from a phase 3 trial.

The National Lipid Association Scientific Sessions will be held Thursday to Sunday and will spotlight emerging areas of research such as “cardio-rheumatology,” a renewed push to reinstate LDL as a health system quality metric and more.

In two phase 2b trials, RNA interference agents were associated with reductions in triglycerides compared with placebo for patients with mixed hyperlipidemia.

An umbrella review of 2 decades of research showed that vegan and vegetarian diets were associated with a greater lipid profile and reduced risk for cancer and death.

Adults in France who consumed more food additive emulsifiers had increased risk for type 2 diabetes, according to a study published in The Lancet Diabetes & Endocrinology.

The disease of obesity often brings cardiometabolic consequences, including hypertension, which remains the most potent and predictive risk factor for cardiovascular disease.

Today, we are closer than ever to achieving the weight loss seen with bariatric surgery, and we are starting to see emerging evidence of cardiovascular risk reduction, type 2 diabetes remission, improvement in heart failure with preserved ejection fraction (HFpEF) and more. This “new” class of medications has been around for more than 18 years. We know the safety profiles; they are manageable.

Individuals prescribed the antidiabetes treatment metformin less likely developed a myeloproliferative neoplasm —potentially also reducing a person’s chances for developing certain cancers — according to data published in Blood Advances.

In patients with type 2 diabetes who underwent ablation for atrial fibrillation, those taking a GLP-1 receptor agonist had lower risk for AF recurrence, mortality and other outcomes, researchers reported at Heart Rhythm 2024.